Astec LifeSciences Limited — Board Meeting, 23-04-2025: Outcome of Board Meeting

The board has approved the financial results for the quarter and half-year, demonstrating a significant year-on-year revenue growth of 25% to ₹150 Cr. Net profit surged by 30% to ₹40 Cr. Additionally, a dividend of ₹5 per share was declared, reflecting strong cash flow and commitment to shareholder returns. The board also greenlit a fundraising initiative, aiming to raise ₹100 Cr to support expansion plans and strengthen operational infrastructure. These strategic decisions position the company for continued growth in a competitive market.